Stock Code: 002399 Stock Abbreviation: Hepalink Announcement No.: 2026-004 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announcement on the 2025 Profit Distribution Proposal The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Deliberation Procedures Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held the 20th meeting of the Sixth Board of Directors on March 30, 2026. The "2025 Profit Distribution Proposal" was unanimously approved. This proposal needs to be submitted to the Company's 2025 Annual Shareholders' Meeting for deliberation.
II. Basic Information on the Profit Distribution and Capital Reserve Increase Plan Audited by Ernst & Young Hua Ming Certified Public Accountants (Special General Partnership), the Company's net profit attributable to shareholders of the listed company in the consolidated statements for 2025 was RMB 349,485,811.78, and the net profit in the parent company statements was -RMB 203,049,684.51. According to the "Company Law" and the "Articles of Association," no further 10% statutory common reserve fund will be withdrawn. As of December 31, 2025, the distributable profit in the parent company statements totaled RMB 214,046,629.84.
The Company's 2025 profit distribution proposal is as follows: Based on the total share capital of 1,467,296,204 shares at the end of 2025, a cash dividend of RMB 1.45 (tax included) will be distributed per 10 shares, totaling RMB 212,757,949.58 in cash dividends. The remaining profit will be retained as undistributed profit. No bonus shares will be issued, and no capital reserve will be used to increase share capital.